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Introduction: Biokinetic models developed for healthy humans are not appropriate to 14 
describe biokinetics in thyroid cancer patients following thyroidectomy. The aim of this study 15 
was to adjust the population model for iodine proposed by the International Commission on 16 
Radiological Protection (ICRP) for the use in these patients. 17 
Method:  Rate constants of the ICRP publication 128 model for iodine were adjusted using 18 
the population modelling software package Monolix to describe activity retention in whole-19 
body, thyroid, blood and protein-bound iodine observed in 23 patients. The new set of rate 20 
constants was compared to the four uptake scenarios proposed in ICRP publication 128. 21 
Results: Flow from the inorganic iodide in blood compartment into the first thyroid 22 
compartment decreases to 0.15 day-1 compared to a value of 7.27 day-1 for the ICRP 23 
publication 128 model with a medium uptake. The transfer from first to second thyroid 24 
compartments and the outflow from the second thyroid compartment increases. An increased 25 
turnover rate of extrathyroidal organic iodine is observed. The rate constant from inorganic 26 
iodide in blood to kidney was also adjusted. Overall a good agreement was found between 27 
the adjusted model and the activity retention in thyroid cancer patients. 28 
Conclusions: The adjustment of population pharmacokinetic models to describe the 29 
biokinetic properties of specific patient populations for therapeutic radiopharmaceuticals is 30 
essential to capture the changes in biokinetics. The proposed set of rate constants for the 31 
established ICRP publication 128 model can be used to more accurately assess radiation 32 
protection requirements for the treatment of thyroid cancer patients using radioiodine. 33 
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The International Commission on Radiological Protection (ICRP) has published biokinetic 37 
models for many commonly used radiopharmaceuticals (1). These models have been used to 38 
calculate dose coefficients for administration of radionuclides to patients.  For patients 39 
undergoing diagnostic examinations in nuclear medicine, absorbed doses to organs and 40 
tissues are often calculated following the Committee on Medical Internal Radiation Dose 41 
(MIRD) formalism (2) using dosimetric models with human computational phantoms and the 42 
respective radiopharmaceutical biokinetic model (3). ICRP models are employed to assess 43 
radiation protection requirements for patients in the nuclear medicine (NM) and molecular 44 
radiotherapy (MRT) settings, and to provide radiation protection guidance to staff, patients and 45 
caregivers (4-6). 46 
A biokinetic model incorporating normal thyroid function (1, 7, 8) is not appropriate to describe 47 
the use of radioiodine to treat residual tissue following partial or total thyroidectomy in thyroid 48 
cancer patients. The biokinetics in these patients are significantly affected by partial or total 49 
removal of the thyroid gland and the use of recombinant thyroid-stimulating hormone (rhTSH) 50 
or thyroid hormone withdrawal (THW) (9). Excretion of radioiodine from the body is often 51 
faster. ICRP publication 128 (ICRP128) provides iodine biokinetics for blocked, low, medium 52 
and high thyroid function. No rate constants are provided in ICRP128 for patients following 53 
thyroidectomy and activity retention in the thyroid remnant cannot be described with the 54 
scenarios considered in ICRP128 (1). 55 
Population pharmacokinetic modelling is used to study a substance’s absorption, distribution, 56 
metabolism, and excretion in a population of interest, such as a population with a specific 57 
pathology. Population pharmacokinetic modelling using non-linear mixed effects (NLME) 58 
allows for inter-patient variability by including both fixed and random effects (10). Simplistic 59 




although more complex models are required to include major organs for radiation protection 61 
purposes.  62 
A set of rate constants for the established ICRP128 biokinetic model was developed here for 63 
radioiodine treatment of thyroid cancer following thyroidectomy. The rate constants of the 64 
ICRP128 population biokinetic model were adapted using NLME to describe the 65 
pharmacokinetics of radioiodine in a thyroid cancer patient cohort based on actual patient 66 
data. These were compared to radioiodine pharmacokinetics in healthy individuals 67 
represented by the established ICRP models. 68 
Method 69 
Radioiodine therapy patient data 70 
Thyroid remnant, whole-body and blood activity retention data were taken from a study by 71 
Flux et al (14). 23 patients, 15 female and 8 male, were administered with a nominal activity 72 
of 3000 MBq of 131I-NaI. Patients were either not given thyroid hormone replacement between 73 
surgery and ablation or thyroid hormones were discontinued for 14 days prior to radioiodine 74 
treatment. No rhTSH was used in this study. The median age of patients was 41 years (range 75 
18-70 years). Only patients with near-total or complete thyroidectomy were included in the 76 
study. Furthermore, patients were excluded from the study if: they had distant metastases at 77 
presentation, were treated with external beam radiotherapy or had been administered with 78 
iodine-containing contrast, 123I or 131I tracers in the three preceding months before 79 
administration of the therapeutic dose of 131I. 80 
Activity retention in the thyroid remnant was obtained from a minimum of three SPECT 81 
acquisitions covering the neck and superior mediastinum using a Philips Forte gamma 82 
camera. Scans were performed at nominally 24, 48 and 72 hours post administration. Two 83 
patients had an additional scan at 96 hours and one patient had an additional scan at 32 hours. 84 




Blood samples were taken at 24, 48, 72 and 144 hours post administration. Protein bound 86 
iodine (PBI) was extracted from blood. The major constituents of PBI are the thyroid 87 
hormones, triiodothyronine (T3) and thyroxine (T4) (16, 17). Activity concentration of iodide 88 
and PBI in blood were determined and converted to total activity in blood with the assumption 89 
of a total blood volume of 5300 ml for adult males and 3900 ml for adult females (18). Whole-90 
body retention measurements were performed directly after administration (baseline value) 91 
and at regular intervals until discharge of the patient. 92 
All activity retention measurements were decay corrected back to the time of administration. 93 
Further details about data acquisition and processing are provided in Flux et al (14). 94 
Model adjustment 95 
Monolix 2019R2 (Antony, France: Lixoft SAS, 2019) was used for NLME modelling. The 96 
structural base model of ICRP128, including the human alimentary tract model from ICRP 97 
publication 100 (ICRP100) (19), was implemented as shown in Figure 1. A combined error 98 
model was chosen for the residual errors with a log-normal residual error distribution (20). 99 
Fitted rate constant distributions were assumed to be log-normally distributed to ensure 100 
positivity of the values on all parameters. The ICRP128 model with the medium uptake rate 101 
constants in the thyroid was used as a base model. 102 
The iodine biokinetics in this patient cohort may differ from a healthy euthyroid population for 103 
several reasons. Patients have undergone thyroidectomy and, as a result of THW, become 104 
hypothyroid and have increased thyroid stimulating hormone (TSH) levels which regulate 105 
sodium iodide symporter (NIS) expression in thyroid tissue (21). 106 
The trapping rate of iodide into thyroid from blood depends in part on thyroid blood flow and 107 
NIS expression. This process is described in the model by the rate constant from Blood 1 to 108 
Thyroid 1. The altered blood supply to the thyroid remnant following thyroidectomy and 109 
increased NIS expression resulting from high TSH (21) should affect the rate of iodide 110 




Several stages of organification of iodide to thyroid hormone are upregulated by increased 112 
TSH levels (21-23). Additionally, Robertson et al found an increased organification rate in 113 
thyrotoxic patients compared to euthyroid patients (22). Therefore, a change in the rate 114 
constant from Thyroid 1 to Thyroid 2 may also be expected given the hypothyroid condition of 115 
thyroid cancer patients under THW and increased TSH levels. The rate of secretion of thyroid 116 
hormone (T3 and T4) from thyroid to blood, which is described by the rate constants from 117 
Thyroid 2 to Blood 2, increases with TSH (8, 24). 118 
Reductions in glomerular filtration rate (GFR) (25, 26), tubular secretion and re-absorption (26) 119 
in hypothyroid patients have been reported. Duranton et al measured increased serum 120 
creatinine in patients under THW (27). Excretion of iodide by glomerular filtration is accounted 121 
for by the rate constant from Blood 1 to Urinary bladder contents. 122 
The ratio of T3 to T4 is elevated with rising TSH levels (24, 28-31). This is expected to result 123 
in an increased turnover rate of extrathyroidal organic iodine due to the higher turnover rate 124 
of T3 compared to T4 (32, 33). The turnover of extrathyroidal organic iodine is represented by 125 
three rate constants, namely Kidney 2 to Blood 1, Liver 2 to Blood 1 and Other 4 to Blood 1. 126 
The turnover is assumed to occur at the same rate from all three compartments (8). 127 
The seven rate constants described above and indicated in red in Figure 1 were allowed to 128 
vary in the fitting to the thyroid cancer patient data set. We could find no further evidence in 129 
literature to support the adjustment of any of the remaining rate constants from the values 130 
published in ICRP100 and ICRP128. It should be noted that in the current model voiding was 131 
modelled as a constant excretion (8) which differs from the excretion model proposed by ICRP.  132 
In the fit process, compartmental model rate constants were varied iteratively to achieve the 133 
best agreement between activity retention observed in patients and predictions by the 134 
compartmental model. For this purpose, thyroid activity retention in patients was taken to be 135 
the sum of thyroid compartments 1 and 2 in the model. Furthermore, patient whole-body 136 




and urine. The blood and PBI activity retention data were assumed to correspond to Blood 1 138 
and Blood 2 compartments, respectively, with Blood 1 being the inorganic iodide and Blood 2 139 
the organic iodine in blood. 140 
 141 
 142 
Figure 1: The structural base model implemented in Monolix. Rate constants shown in red were tested 143 
during the model building process. In the base model, Blood 1 is the inorganic iodide in blood, Blood 2 is 144 
the organic iodine in blood, Thyroid 1 is the inorganic iodide in the thyroid, Thyroid 2 is the organic iodine 145 
in the thyroid, Kidney 1 is the inorganic iodide in kidneys, Kidney 2 is the organic iodine in kidneys, and 146 
Liver 1 is the inorganic iodide in liver, Liver 2 is the organic iodine in liver. Other 1 to Other 4 represent any 147 
tissues not specifically included in the model. Salivary Gl are the salivary glands, St Wall is the stomach 148 
wall, St Contents are the stomach contents, SI are the small intestines, RC is the right-sided colon, LC is 149 
the left sided colon, RS is the rectosigmoid, Kidney 3 is an additional kidney compartment in the ICRP128 150 
model representing transfer to the bladder and Bladder C are the bladder contents. All rate constants are 151 




Model comparison to ICRP128 153 
Model predictions of the final population model were compared to individual observations in 154 
patients. The biological retention predictions in each compartment of the final population 155 
model were compared to the predictions of the ICRP128 base model. 156 
Results 157 
Model adjustment 158 
Rate constants of the updated ICRP128 population model developed here are presented in 159 
Table 1 and compared to the respective rate constants of the ICRP128 base model. Flow from 160 
the inorganic iodide in blood compartment (Blood 1) into the first thyroid compartment (Thyroid 161 
1) decreases, the rate constant from inorganic iodide in thyroid (Thyroid 1) to organic iodine 162 
in thyroid (Thyroid 2) approximately doubles and outflow from the second thyroid compartment 163 
(Thyroid 2) increases by two orders of magnitude. Transfer from inorganic iodide in blood 164 
(Blood 1) to Kidney 3 is found to be lower than in the ICRP128 model. The  turnover rate of 165 
extrathyroidal organic iodine, represented by the three rate constants from Kidney 2, Liver 2 166 
and Other 4 to inorganic iodide in blood (Blood 1), is estimated to increase from 0.14 day-1 to 167 









Table 1: Comparison of rate constants of the ICRP128 base model and the adjusted rate constants for the 174 











kB1T1 Blood 1 → Thyroid 1 7.27 0.15 
KT1T2 Thyroid 1 → Thyroid 2 95 181 
kT2B2 Thyroid 2 → Blood 2 0.0077 0.50 
kB1K3  Blood 1 → Kidney 3 11.83 6.87 
kK2B1, kL2B1, 
kO4B1 
Kidney 2 → Blood 1, Liver 2 → Blood 
1, Other 4 → Blood 1 
0.14 0.29 
 177 
Figure 2 shows the predictions of the thyroid cancer patient model, compared to the 178 
predictions of the ICRP128 base model for the different uptake scenarios considered and the 179 
observed activity retention in patients. Predicted and measured activity retention in 180 
compartments has been corrected for physical decay. A good agreement was found between 181 





Figure 2: Comparison of predictions of the final population model for thyroid cancer patients administered 184 
with 3000 MBq of 131I-NaI (red solid line) obtained from a fit of rate constants kB1T1, kT1T2, kT2B2, kB1K3, kK2B1, 185 
kL2B1 and kO4B1, of the ICRP128 base model, to patient data of Flux et al (14) (red diamonds). The predictions 186 
of the ICRP128 model for blocked thyroid (yellow dashed line), low (blue dashed line), medium (black 187 
dashed line) and high (green dashed line) uptake are presented for comparison. Activity retention was 188 
decay corrected back to the administration time and, therefore, biological retention is presented excluding 189 
physical decay. 190 
Model comparison to ICRP128 191 
 Population model predictions were compared to the observed values in the 23 patients 192 
(Figure 2 and Figure 3). Predicted and observed whole-body and blood retentions are in good 193 
agreement, while the population model appears to perform less well to predict the variability 194 






Figure 3: Comparison of population model predictions to observations in patients for activity retention in  198 
(a) whole-body, (b) thyroid remnant, (c) blood and (d) PBI after a 3000 MBq 131I-NaI administration. 199 
As shown in Figure 2, the model with rate constants to describe a post-thyroidectomy thyroid 200 
cancer patient population shows a slower clearance from blood compared to ICRP128 while 201 
whole-body excretion is faster than the low, medium and high uptake scenarios in the 202 
ICRP128 model and slower than the blocked thyroid scenario. Thyroid activity retention peaks 203 
at 1.0% of the administered activity, which is markedly lower, compared to the low, medium 204 
and high uptake scenarios of ICRP128 of approximately 19%, 30% and 40% uptake in the 205 
thyroid. Maximum uptake in the thyroid remnant is predicted to occur around 29 hours, which 206 
is slightly faster than for the low, medium and high uptake scenarios of ICRP128 where peak 207 





Results presented here highlight the necessity of adjusting population pharmacokinetic 210 
models to describe the biokinetic properties of specific patient populations for therapeutic 211 
radiopharmaceuticals. Current ICRP models have been developed based on data from 212 
healthy human or animal studies although biokinetic properties may change for patient 213 
populations undergoing treatment. It has been shown here that the development of a patient-214 
specific population biokinetic model is feasible even with a limited number of patients and 215 
measurements per patient.  216 
The markedly faster urinary excretion predicted from this model, which has also been 217 
observed in previous studies (34, 35), is an important factor in the MRT setting as it will affect 218 
radiation protection guidance provided to staff, patients and caregivers. The model proposed 219 
here with lower iodine uptake in the thyroid and faster urinary excretion compared to ICRP128, 220 
provides a more accurate estimate of activity retention in this patient cohort. This could inform 221 
radiation protection restrictions based on relevant national legislative requirements. 222 
The observed increased rates of organification of iodide and secretion of thyroid hormones 223 
are in agreement with literature evidence due to the high TSH caused by THW (21-24, 36). In 224 
addition, the expected increase in turnover rate of extrathyroidal organic iodine identified from 225 
literature (32, 33) was confirmed in the present model. Also in agreement with literature (25-226 
27), the excretion of iodide by glomerular filtration decreased. 227 
A patient-specific pharmacokinetic model for dose assessment following radionuclide therapy 228 
may require rate constants to be derived from either patient-specific covariates as part of a 229 
physiologically-based pharmacokinetic (PBPK) model (37), or by adjustment of models to 230 
patient-specific activity retention measurements (38).  No patient-specific covariates were 231 
added during the model development due to the small number of patients included in this 232 
retrospective analysis. Inter-individual random effects, therefore, remain unexplained in the 233 




individual patient biokinetics, especially for activity retention in the thyroid remnant, as 235 
demonstrated by Figure 3. EANM, EFOMP, EFRS, ESR and ESTRO have published a 236 
common strategic research agenda for radiation protection in medicine (39), which includes 237 
the refinement, validation and implementation of new biokinetic models for dosimetry in MRT. 238 
A prospective study following a defined population modelling plan as defined in current best-239 
practice guidelines (40) should be performed to develop a more accurate model that could 240 
potentially be used for individual patient biokinetic predictions which would enable 241 
individualised radiation protection restrictions and could be used in the dose assessment. The 242 
model presented here will be validated and extended using activity retention data and 243 
covariates for 100 patients collected as part of a concurrent series of non-randomised, non-244 
blinded, prospective observational studies at four centres (Royal Marsden Hospital, 245 
Universitätsklinikum Marburg, Universitätsklinikum Würzburg and Institute Universitaire du 246 
Cancer de Toulouse Oncopole) as part of MEDIRAD Work Package 3 (41, 42).  247 
Limitations of the current study include the relatively small patient sample and the fact that 248 
data were only available for patients administered with a fixed activity of 3000 MBq, and 249 
without rhTSH stimulation. Hänscheid et al (35) have shown that the effective half-time in 250 
remnant thyroid tissue varies based on the patient preparation prior to radioiodine therapy, 251 
namely rhTSH stimulation or THW. Furthermore, Ito et al presented results that the T3/T4 ratio 252 
is lower in patients with total thyroidectomy during levothyroxine therapy when compared to 253 
control (31). Therefore, a further model might be required for the sub-population of patients 254 
administered under rhTSH stimulation. The model should also be validated for varying 255 
amounts of administered activities. Nevertheless, the model has proven to accurately describe 256 
the patient biokinetics for the patient cohort presented here. 257 
Conclusions 258 
A set of rate constants was developed for the established ICRP128 model to accurately 259 




here can be used to more accurately assess radiation protection requirements for the 261 
treatment of thyroid cancer patients using radioiodine. 262 
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